- 询价
- MedChemExpress(MCE)
- 美国
- HY-152076
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
香烟烟雾如何加速声带纤维化？CD44-透明质酸轴是关键通路Takara 秋促来袭，提取+反转录+定量套装仅 1200 元abinScience 体内级抗体 全年锁价 低至 ￥1200阿拉丁 22万+ 科研级产品现货速发，品质严控、科研无忧- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Please store the product under the recommended conditions in the Certificate of Analysis.
- 库存：
货期：询盘
- 供应商：
MedChemExpress LLC
- CAS号：
2892295-10-0
- 规格：
询盘
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Telomerase-IN-4
CAS No. : 2892295-10-0
MCE 国际站：Telomerase-IN-4
产品活性：Telomerase-IN-4 是一种有效的端粒酶 (telomerase) 抑制剂。Telomerase-IN-4 具有抗增殖活性，诱导细胞凋亡 (apoptosis)。
研究领域：Apoptosis
作用靶点：Apoptosis
In Vitro: Telomerase-IN-4 (compound 8e; 0.1-100 μg/mL; 72 h) has antitumor effects against both cancer cell lines with IC50 values of 9.47 and 17.09 μg/mL for MCF-7 and A549 cells, respectively.
Telomerase-IN-4 (9.467 μg/mL; 48 h) arrests cell cycle at the S phase and induces apoptosis in MCF-7 cells.
In Vivo: Telomerase-IN-4 (5 mg/kg; i.p.; three times per week for two weeks; Swiss albino female mice) has anticancer activity and inhibits tumor growth.
相关产品：MG-132 | Doxorubicin hydrochloride | Bafilomycin A1 | LY294002 | Tamoxifen | Paclitaxel | Y-27632 | Acetylcysteine | Angiotensin II human | 2-Deoxy-D-glucose | Staurosporine | SB-431542 | Actinomycin D | Deferoxamine mesylate | Bortezomib | 5-Fluorouracil | Trametinib | Sorafenib | Oxaliplatin | Gemcitabine | Temozolomide | Rotenone | Mdivi-1 | Elesclomol | Ruxolitinib | Decitabine | SP600125 | MK-2206 dihydrochloride | Etoposide | Monomethyl auristatin E
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Analysis of Telomerase RNA Gene Expression by In Situ Hybridization
The regulation of telomerase activity is likely to be a complex issue, involving the transcriptional activity of the telomerase RNA component gene, (hTR) and the telomerase catalytic component gene (hTRT), as well as the interaction
In Situ Analysis of Telomerase RNA Gene Expression as a Marker for Tumor Progression
), and the interaction of telomerase with other telomere associated proteins ( 10 , 15 – 20 ; see Fig. 1 ). The use of telomerase as a diagnostic marker and target for cancer therapy relies on the development of reliable assays and technologies to detect telomeres
telomerase activity, which requires large amounts of telomerasepositive cells (2�108 ), thus limiting the number of primary human specimens that could be examined easily (9 ,10 ). A major problem with the conventional assay is also the weak signal strength
技术资料暂无技术资料 索取技术资料
